<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2014-05-12 16:15:42Biology Coagulation Antithrombin Thrombin Heparin Factor VIII Factor X Fibrinogen Anticoagulant Blood Coagulation system Anatomy |
Add to Reading List |
WFH 2014 World Congress Medical Free Paper 8 ALN‐AT3: An Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia May 15, 2014 | REGULAR ARTICLE CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise na¨ıve and memory cells ´ ` 1DocID: 1tX4g - View Document |
 | News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web SitesDocID: 1qHpD - View Document |
 | For immediate release 26 May 2016 AFSTYLA® (rFVIII-Single Chain) – FDA approval CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [AntihaemoDocID: 1oCE0 - View Document |
 | 13308 FT Factor VIII Plasma déficientDocID: 1odr2 - View Document |
 | UPDATE: Baxalta’s BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A •DocID: 1kAcN - View Document |